Prognostic and Diagnostic Value of Plasma Soluble Suppression of Tumorigenicity-2 Concentrations in Acute Respiratory Distress Syndrome
Authors:
- 1 November 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 41 (11) , 2521-2531
Abstract
Objectives: Soluble suppression of tumorigenicity-2 is a biomarker of myocardial strain and inflammation. The characteristics of acute respiratory distress syndrome include inflammation and cardiovascular dysfunction. We sought to determine whether plasma soluble suppression of tumorigenicity-2 concentration is associated with outcome and response to conservative fluid management and whether soluble suppression of tumorigenicity-2 concentration discriminates acute respiratory distress syndrome from decompensated heart failure. Design: A retrospective analysis of the Fluid and Catheter Treatment Trial, a multi-center randomized controlled trial of conservative fluid management in the acute respiratory distress syndrome, as well as of a cohort of patients with decompensated heart failure. Setting: Twenty acute care hospitals. Patients: Eight hundred twenty-six patients with acute respiratory distress syndrome and 209 patients with acutely decompensated heart failure. Measurements and Main Results: Nonsurvivors had higher day 0 (p < 0.0001) and day 3 (p < 0.0001) soluble suppression of tumorigenicity-2 concentrations. After adjustment for severity of illness, higher soluble suppression of tumorigenicity-2 concentration was associated with mortality, with odds ratioadj 1.47 (95% CI, 0.99–2.20; p = 0.06) at day 0, 2.94 (95% CI, 2.00–4.33; p < 0.0001) at day 3, and 3.63 (95% CI, 2.38–5.53; p < 0.0001) if soluble suppression of tumorigenicity-2 increased between days. Cumulative fluid balance was more positive among patients with higher day 0 (median, 5,212 mL [interquartile range, 200–12,284 mL] vs median, 2,020 mL [interquartile range, –2,034 to 7,091 mL]; p < 0.0001) and day 3 soluble suppression of tumorigenicity-2 (median, 7,678 mL [interquartile range, 2,217–14,278 mL] vs median, 1,492 mL [interquartile range, –2,384 to 6,239 mL]; p < 0.0001). Soluble suppression of tumorigenicity-2 showed excellent discriminative ability between the Fluid and Catheter Treatment Trial and heart failure populations (area under receiver-operating characteristic curve = 0.98; p < 0.0001). Conclusions: Higher soluble suppression of tumorigenicity-2 concentrations are associated with worse outcome in acute respiratory distress syndrome and may have value for discriminating acute respiratory distress syndrome from heart failure.Keywords
This publication has 34 references indexed in Scilit:
- Prognostic and Pathogenetic Value of Combining Clinical and Biochemical Indices in Patients With Acute Lung InjuryChest, 2010
- Interleukin-33 Prevents Apoptosis and Improves Survival After Experimental Myocardial Infarction Through ST2 SignalingCirculation: Heart Failure, 2009
- Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma — The Presage™ ST2 assayClinica Chimica Acta, 2009
- Diagnosing acute lung injury in the critically ill: a national survey among critical care physiciansActa Anaesthesiologica Scandinavica, 2009
- Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart FailureJACC, 2008
- Prognostic value of plasma N-terminal probrain natriuretic peptide levels in the acute respiratory distress syndrome*Critical Care Medicine, 2008
- Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial InfarctionCirculation, 2008
- Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders*Critical Care Medicine, 2007
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryCritical Care, 2007
- ST2 GENE INDUCED BY TYPE 2 HELPER T CELL (TH2) AND PROINFLAMMATORY CYTOKINE STIMULI MAY MODULATE LUNG INJURY AND FIBROSISExperimental Lung Research, 2007